LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Inicio・Lista de Acciones・KalVista Pharmaceuticals Inc

KalVista Pharmaceuticals Inc

Cerrado

SectorSanidad

26.74 -0.07

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

26.73

Máximo

26.77

Métricas clave
By Trading Economics
Ingresos	55M -5.4M
Ventas	-2.9M -1.4M
BPA	0.94
Margen de beneficios	376.718
Empleados	275
EBITDA	-2.3M -61M

Recomendaciones
By TipRanks
Recomendaciones	Neutral
Estimación a 12 Meses	+8.84% upside

Dividendos
By Dow Jones
Próximas Ganancias	21 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	870M 1.4B
Apertura anterior	26.81
Cierre anterior	26.74

Noticias sobre sentimiento de mercado

By Acuity

33%

67%

88 / 345 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

12.19 / 12.825 Soporte y Resistencia

KalVista Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

25 sept 2025, 17:27 UTC

Principales Movimientos del Mercado

KalVista Pharmaceuticals Shares Drop After Notes Offering Prices

7 jul 2025, 11:30 UTC

Principales Movimientos del Mercado

KalVista Pharmaceuticals Shares Rise on FDA Approval of Hereditary Angioedema Drug

31 mar 2026, 21:33 UTC

Adquisiciones, fusiones, absorciones

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31 mar 2026, 20:36 UTC

Adquisiciones, fusiones, absorciones

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

Comparación entre iguales

Cambio de precio

KalVista Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

8.84% repunte

Estimación a 12 Meses

Media 29.17 USD 8.84%

Máximo 35 USD

Mínimo 27 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para KalVista Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

8 ratings

Comprar

Mantener

Vender

De acuerdo con 8 analistas que ofrecen calificaciones bursátiles a para KalVista Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

12.19 / 12.825Soporte y Resistencia

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

Sentimiento

By Acuity

88 / 345 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de KalVista Pharmaceuticals Inc

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.